Showing 7231-7240 of 8826 results for "".
- FDA Approves sNDA for Roflumilast Cream, 0.15%, for Mild-to-Moderate ADhttps://practicaldermatology.com/news/fda-approves-snda-roflumilast-cream-015-mild-moderate-ad/2467287/The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild-to-moderate atopic dermatitis (AD) in adult and pediatric patients 6 years of age and older, Arcutis Biotherapeutics, Inc. announc
- Platelet-Rich Plasma Improves Outcomes in Severe ADhttps://practicaldermatology.com/news/platelet-rich-plasma-improves-outcomes-severe-ad/2467268/A new study looking at platelet-rich plasma (PRP) as an adjuvant therapy for adult atopic dermatitis (AD) suggested the treatment was associated with favorable outcomes. The literature search focused on original English-language articles about PRP as a therapeutic method for adult AD. Revi
- Almirall Announces New Sustainability Strategyhttps://practicaldermatology.com/news/almirall-announces-new-sustainability-strategy/2467252/The five pillars of Planet, People, Patients, Partners, and Principles are at the center of Almirall S.A.’s new sustainability strategy, Act4Impact 2030, the company announced. The updated strategy aims at transforming the company’s sustainability roadmap and consists of 20 strategic lines
- Promotional vs. Educational: Skin Condition Posts on Instagram and TikTokhttps://practicaldermatology.com/news/promotional-vs-educational-skin-condition-posts-instagram-and-tiktok/2467249/New research revealed differences in the types of dermatology content present on the Instagram and TikTok social media platforms. Researchers publishing in the Journal of Drugs in Dermatology looked specifically at content on the Instagram and TikTok social media platforms relat
- Survey: Just 40% See Dermatologists Annually Despite Skin Concernshttps://practicaldermatology.com/news/survey-just-40-see-dermatologists-annually-despite-skin-concerns/2467226/Manufacturer CeraVe has announced findings from a new survey suggesting that while 80% of participants experienced skin concerns, just 40% of them visited a dermatologist for an annual skin exam. The survey of 1,000 American adults also revealed that 25% suffered from serious skin condit
- Dermavant Receives Approval of Tapinarof for Psoriasis and Atopic Dermatitis in Japanhttps://practicaldermatology.com/news/dermavant-receives-approval-tapinarof-psoriasis-and-atopic-dermatitis-japan/2467170/Dermavant Sciences announced that Japan Tobacco has received approval in Japan for tapinarof c
- Smoking, BMI, and Age Affect Biologic Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/smoking-bmi-and-age-affect-biologic-outcomes-psoriasis-analysis/2467138/A new systematic review and meta-analysis revealed a number of factors that can make patients with psoriasis have a poorer response to biologics. Researchers for the study used data from PubMed, Embase, and Web of Science reporting treatment outcomes using Psoriasis Area and Severity Ind
- DermTech Files for Voluntary Chapter 11 Protectionhttps://practicaldermatology.com/news/dermtech-files-voluntary-chapter-11-protection/2467087/DermTech announced it has filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the company’s strategic alternatives review process. DermTech, which is a provider of noninvasive skin genomics technol
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://practicaldermatology.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study